Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: EC:3.4.24.11 (CD10)
 9,792 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Thyroid hormones are synthesized within the thyroglobulin (Tg) molecule and must be released to reach the circulation and exert their metabolic effect. We have previously shown that three lysosomal endopeptidases, cathepsin B, D, and L, are active in the early stages of intrathyroidal degradation of Tg but do not themselves release free hormone. The current study examines the role of exopeptidases as the next step in thyroid hormone release. Human thyroidal cathepsin B and two partially purified exopeptidases, dipeptidyl peptidase II (DP-PII) and lysosomal dipeptidase I (LDPI), were used to digest the 20-kDa N-terminal peptide of rabbit Tg, which contains the dominant T4 site of Tg at residue 5. Cathepsin B acted as an endopeptidase initially, producing small T4-containing peptides. After more extended digestion, it also acted as an exopeptidase, producing the dipeptide T4-Gln, corresponding to residues 5 and 6 of Tg. Lysosomal dipeptidase I alone had no effect on 20 kDa but acted in combination with cathepsin B to release T4 from the T4-Gln dipeptide. Although addition of DPPII increased the release of hormone from 125I-Tg by an extract of DPPII-deficient lysosomes, it had no apparent effect on the degradation of the 20-kDa peptide, either alone or in combination with cathepsin B or LDPI. Thus DPPII may act in synergy with some other endopeptidase, or alternatively, may play a role in the release of hormone from other sites in Tg. We conclude that the N-terminus of Tg, which contains its major hormonogenic site, is particularly susceptible to hydrolysis by the endopeptidase cathepsin B and that cathepsin B additionally has an important exopeptidase action that allows it to release a T4 dipeptide that is then further degraded by LDPI to release free T4.
 ...
PMID:The combined action of two thyroidal proteases releases T4 from the dominant hormone-forming site of thyroglobulin. 875 51

B lymphocytes that infiltrate the thyroid (Thy-B cells) in Graves' patients appear to be implicated in the pathophysiology of this disorder. The goal of the present study was to examine the nature of these Thy-B cells. To this end, Thy-B lymphocytes were isolated from surgical thyroidal samples, and their phenotype was determined by using mouse monoclonal antibodies (mAb) directed against a wide variety of surface markers, followed by flow cytometry multicolor analysis. The results show that most Thy-B cells (approximately 60%) exhibited IgM(+) IgD(low to -) surface immunoglobulin (Ig) profile, whereas the minor cell fraction (approximately 30%) consisted of switched IgG(+) memory B lymphocytes. Thy-B cells expressed low levels of CD5, CD23, and CD62L, which distinguished them from the resting B-cell pool, the major B-cell subset in the blood. In addition, they lacked CD38, CD10, and CD71, characteristic molecules for the germinal center B lymphocytes. In addition, Thy-B lymphocytes showed peculiar patterns both of adhesion molecules (CD62L(-), CD44(intermediate)), and of activation molecules (CD69(+), CD80(+), and, in part, CD95(+)). Taken together, these results suggest that the Thy-B lymphocyte subset consists of a combination of IgM(+) B cells resembling marginal zone B lymphocytes, and isotype-switched memory B cells.
Thyroid 2001 Jun
PMID:Thyroid-infiltrating B lymphocytes in Graves' disease are related to marginal zone and memory B cell compartments. 1144 98

CD10/neutral endopeptidase 24.11(NEP) is a membrane-bound zinc metalloproteinase the expression of which represents a useful tool in the classification and diagnosis of malignant leukemia and lymphoma. Recently, CD10 has been found to be expressed in nonhematopoietic tissues and various types of neoplasms. In this study, we examined CD10 immunostaining in paraffin sections of 70 distinct lesions to investigate whether CD10 is a useful diagnostic marker for thyroid neoplasms. CD10 was not detected in normal thyroid tissue, benign lesions (15 follicular lesions and 15 adenomatous goiters), and pure papillary carcinomas except for follicular variants. In contrast, CD10 was expressed in 8 of 10 (80%) follicular carcinomas and 7 of 9 (77%) follicular variant of papillary thyroid carcinomas. This appears to be the first report on the expression of this member of a newly identified gene family in thyroid tumors. In conclusion, immunohistochemistry of CD10 in paraffin sections is valuable in the classification of thyroid follicular lesions into benign and malignant groups and in the diagnosis of follicular variant of papillary thyroid carcinoma.
Thyroid 2003 Mar
PMID:CD10 expression is useful in the diagnosis of follicular carcinoma and follicular variant of papillary thyroid carcinoma. 1272 79

The article presents a case of 57-year-old woman with the infiltration of rare small lymphocytic B cell lymphoma in the thyroid gland. Initially, the patient was followed-up due to chronic lymphocytic B-cell leukemia diagnosed on the basis of histopathological examination of cervical lymph node. Eight months later, general symptoms occurred along with lymphocytosis and exacerbation of lesions in lymph nodes, and therefore, chemotherapy was started according to COP regimen. After four chemotherapy cycles, further progression of the disease was observed during chemotherapy. Computed tomography (CT) performed at that time showed generalized lymphadenopathy and the presence of an irregular area in left thyroid lobe. On palpation, the thyroid was asymmetrical, with enlarged left lobe and palpable lymph node packages on the left side of the neck. The levels of thyroid hormones and anti-thyroid antibodies were normal. Ultrasound examination of the thyroid gland showed non-homogeneous hypoechogenic structure of the left lobe and complete focal remodeling. Cytological examination of left-lobe lesion obtained during fine needle aspiration biopsy showed multiple small lymphoid cells, suggestive of small lymphocytic lymphoma. To confirm this diagnosis, flow cytometry of the biopsy material sampled from the left lobe was performed showing B cellimmunophenotype: CD19+/CD20+/CD22 dim/FMC-7, CD23+/CD5+, sCD79b-+, CD38-, CD10-, kappa and lambda-/weak reaction. The results of flow cytometry of the thyroid bioptate and blood were nearly identical, confirming leukemic nature of the infiltration in left thyroid lobe. Cytogenetic findings included the presence of 17p deletion (TP53 gene). The patient received immunochemotherapy with alemtuzumab. The progression of the disease occurred in the sixth week of therapy. The treatment was discontinued after 8 weeks due to worsening of patient's general status. The patient died 15 months after the diagnosis.
Thyroid Res 2013 Jan 02
PMID:Case report: rare case of infiltration of small lymphocytic B-cell lymphoma in the thyroid gland of female patient with B-cell chronic lymphocytic leukemia (CLL-B/SLL-B). 2328 5

Thyroid-like follicular carcinoma of the kidney (TLFCK) is a provisional new entity of renal cell carcinoma (RCC). We herein reported and compared one TLFCK case and one PRCC case with thyroid-like feature. The former entirely consisted of thyroid-like follicular architecture and the tumor cells were diffusely positive for PAX-8, but negative for CK7, AMACR, and CD10. By contrast, both papillary architecture (~60%) and thyroid-like follicular architecture (~40%) were identified in the latter. Tumor cells in both histological components exhibited diffusely positive staining for PAX-8, CK7, AMACR, but negative for CD10. FISH analysis showed no aberration in TLFCK case but trisomy of chromosome 17 in PRCC case. Along with a brief literature review, we presented that recognition of TLFCK is important to distinguish it from other conditions that show thyroid-like features. Additionally, a diagnosis of TLFCK should be cautiously made when papillary component is present in the tumor.
...
PMID:Thyroid-like Follicular Carcinoma of the Kidney and Papillary Renal Cell Carcinoma with Thyroid-like Feature: Comparison of Two Cases and Literature Review. 2666 3

Thyroid-like follicular carcinoma of the kidney (TLFCK) is a rare but emerging renal neoplasm that morphologically mimics follicular carcinoma of the thyroid but lacks immunohistochemical expression of thyroid markers such as TTF-1 and thyroglobulin. Here, a case of an incidentally discovered TLFCK in a 27-year-old man is reported. Histologic evaluation demonstrated an encapsulated proliferation of variably sized thyroid follicle-like epithelial-lined spaces filled with colloid-like eosinophilic secretions. Immunohistochemical analysis confirmed lack of expression of the thyroid markers TTF-1 and thyroglobulin with expression of PAX8 and CD10, confirming a neoplasm of renal origin, which correlated to the clinical and radiographic absence of thyroid pathology. In this report, this case is described with an emphasis on the differential diagnosis.
 ...
PMID:Thyroid-Like Follicular Carcinoma of the Kidney. 2838 Nov 54

A variety of tumors may involve the eyelid, most of which are primary, but rarely can be metastatic. Previously reported eyelid primary carcinomas with neuroendocrine features include Merkel cell carcinoma, apocrine and eccrine gland carcinoma, sebaceous gland carcinoma, and one report of primary "well-differentiated neuroendocrine tumor." Herein we report the first case of primary cribriform carcinoma of the eyelid with neuroendocrine features. The patient is a 75-year-old black man who presented to the clinic with a 5-year history of a slowly growing, non-painful, non-exudative lesion of his left lower eyelid. Examination disclosed a non-tender 8 mm by 9 mm ovoid, firm, euchromic subdermal non-adherent nodule involving the left lower eyelid with no madarosis or loss of lid margin architecture, but with overlying induration. An incisional biopsy demonstrated nodules and aggregates of tumor composed of cuboidal hyperchromatic basoloid cells with occasional mitotic figures within sheets in a mostly cribriform and occasionally papillary pattern. The tumor was diffusely positive for cytokeratin, Epithelial Membrane Antigen, and p40 and focally positive for synaptophysin. The tumor was negative with antibodies for Cytokeratin 20 (CK20), p63, CD10, Thyroid Transcription Factor-1, Cytokeratin 7, Prostate Specific Antigen, and Epithelial Specific Antigen. Oncologic evaluation was negative for metastases. The patient underwent a complete excision of his eyelid tumor with 5 mm margins using Mohs surgery, with subsequent reconstruction using a Hughes tarsoconjunctival flap, myocutaneous advancement flap, and lateral canthal tendon plication. <p><em>J Drugs Dermatol. 2017;16(2):173-174.</em></p>.
 ...
PMID:Primary Cribriform Carcinoma of the Eyelid With Neuroendocrine Features: A Case Report. 2830 Aug 61